

Bronchopulmonary Dysplasia - Pipeline Review, H2 2020

<https://marketpublishers.com/r/BD2D67C7DB9EN.html>

Date: August 2020

Pages: 81

Price: US\$ 2,000.00 (Single User License)

ID: BD2D67C7DB9EN

Abstracts

Bronchopulmonary Dysplasia - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H2 2020, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection, premature babies who have a low birth weight seem to be at greater risk for developing BPD. Treatment includes bronchodilators, diuretics and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).

The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor

projects.

The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Bronchopulmonary Dysplasia - Overview
- Bronchopulmonary Dysplasia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bronchopulmonary Dysplasia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
- Advent Therapeutics Inc
- Airway Therapeutics LLC
- Ayuviz Research Inc
- Chiesi Farmaceutici SpA
- Insmed Inc
- Laboratoire Aguettant SA
- MediPost Co Ltd
- Meridigen Biotech Co Ltd
- Orphanix GmbH
- Radikal Therapeutics Inc
- Syntrix Biosystems Inc
- Takeda Pharmaceutical Co Ltd
- The Cell Factory BVBA
- Trimunocor Ltd
- United Therapeutics Corp
- Windtree Therapeutics Inc
- Bronchopulmonary Dysplasia - Drug Profiles
- Aerosurf - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AT-100 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
AVR-48 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFMEV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrocortisone hemisuccinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchopulmonary Dysplasia - Dormant Projects
Bronchopulmonary Dysplasia - Discontinued Products
Bronchopulmonary Dysplasia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Bronchopulmonary Dysplasia - Pipeline by Advent Therapeutics Inc, H2 2020
Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, H2 2020
Bronchopulmonary Dysplasia - Pipeline by Ayuvis Research Inc, H2 2020
Bronchopulmonary Dysplasia - Dormant Projects, H2 2020
Bronchopulmonary Dysplasia - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bronchopulmonary Dysplasia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Advent Therapeutics Inc
Airway Therapeutics LLC
Ayuvis Research Inc
Chiesi Farmaceutici SpA
Insmed Inc
Laboratoire Aguettant SA
MediPost Co Ltd
Meridigen Biotech Co Ltd
Orphanix GmbH
Radikal Therapeutics Inc
Syntrix Biosystems Inc
Takeda Pharmaceutical Co Ltd
The Cell Factory BVBA
Trimunocor Ltd
United Therapeutics Corp
Windtree Therapeutics Inc

I would like to order

Product name: Bronchopulmonary Dysplasia - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/BD2D67C7DB9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BD2D67C7DB9EN.html>